Recent studies have demonstrated that an extensive peptide identity platform characterizes entities spanning the entire evolutionary arc from viruses to humans. These studies also established existence of an immune cross-reactivity among viruses and bacteria, as well as between microbial organisms and humans. This peptide commonality presents obstacles to diagnostics, burdens therapeutic vaccinology with harmful collateral effects, and can result in autoimmune diseases. The present study 1) recapitulates the significance of cross-reactivity from the molecular mimicry hypothesis to the phenomenon of microbial immunoevasion; 2) analyzes the implications of cross-reactivity for the self-nonself discrimination issue; 3) highlights the negative role exerted by cross-reactions in translating immunology to effective vaccines; 4) outlines the vicious circle connecting peptide commonality, microbial immune escape, adjuvanted vaccines and autoimmune cross-reactions; and 5) conclusively indicates sequence uniqueness as a basic criterion for designing effective vaccines exempt from autoimmune crossreactions.
ABSTRACT
Recent studies have demonstrated that an extensive peptide identity platform characterizes entities spanning the entire evolutionary arc from viruses to humans. These studies also established existence of an immune cross-reactivity among viruses and bacteria, as well as between microbial organisms and humans. This peptide commonality presents obstacles to diagnostics, burdens therapeutic vaccinology with harmful collateral effects, and can result in autoimmune diseases. The present study 1) recapitulates the significance of cross-reactivity from the molecular mimicry hypothesis to the phenomenon of microbial immunoevasion; 2) analyzes the implications of cross-reactivity for the self-nonself discrimination issue; 3) highlights the negative role exerted by cross-reactions in translating immunology to effective vaccines; 4) outlines the vicious circle connecting peptide commonality, microbial immune escape, adjuvanted vaccines and autoimmune cross-reactions; and 5) conclusively indicates sequence uniqueness as a basic criterion for designing effective vaccines exempt from autoimmune crossreactions.
INTRODUCTION: THE "VACCINE PROBLEM"
Immunology has accumulated a tremendous amount of knowledge on the components of the immune system and the structural-functional correlates underlying their function. However, the advantages expected from this massive knowledge have not concretized. Citing verbatim Coutinho: "...we continue to treat allergy as we did before IgE was known, we have no specific therapy for autoimmune diseases, we are unable to tolerize the recipient of an organ to the tissues of the donor, and we seem incompetent to derive vaccines to protect the larger part of the world population from parasite infections" (1). Of note, Coutinho's observations date to more than 20 years ago. At that time, they invoked the importance of investing more in the description of genes, molecules and cells in order to move toward translational medicine. It was also argued that a shift from molecular and cellular immunology to systemic immunology was necessary to address those immunological issues that remained unresolved.
In 2011, we continue to rely mainly on immunosuppressors for treating autoimmune diseases, register data on failed efforts to develop anti-tumor vaccines, and still face limitations in designing effective novel vaccines for infectious diseases. In addition, unfortunately we witness today an ever-rising aversion to vaccination protocols because of the numerous putative and/or real adverse events associated with the vaccine formulations currently in use. It seems science has not been able to explain, overcome, and solve vaccination fears dating back more than two hundred years ago (2).
It is suggested that the data obtained from common experimental mouse models may be inadequate to understand and treat human immunological diseases (3). Moreover, it is said that the experimental conditions used in mouse systems (such as the amounts and routes of administration of the antigen and adjuvant) cannot be extrapolated to humans (4). Here, we suggest that peptide cross-reactivity is a basic factor affecting the efficacy of vaccines and the future of human immunology. In particular, we review the extent and role of peptide cross-reactivity between microbial and human proteins, and suggest that the difficulties in designing "the right vaccines" against infectious agents are possibly intrinsic to the human-affine nature of the microbial proteomes.
ANTIBODIES AND ANTIGENS: CROSS-REACTIVITY BEFORE MONOCLONAL ANTIBODIES
From the beginning of the immunological era, researchers recognized that cross-reactivity was a major obstacle to the development of immunoassay systems, as described in the following brief historical snapshot: 1) In 1939, Eagle and Hogan (5) observed that an alcoholic extract of normal mammalian tissue can be used as 'antigen' instead of the aqueous extract of syphilitic liver, thus rendering the Wassermann reaction a puzzling anomaly among serodiagnostic tests. 2) Antibodies directed against human follicle-stimulating hormone (FSH) failed to distinguish the four human glycoprotein hormones: FSH, luteinizing hormone, chorionic gonadotropin, and thyrotropin (6). 3) Even immunoassay of aldosterone, a small molecular weight compound, was subjected to the interference such as that exerted by hydroxylated metabolites of spirolactones (7). 4) Extensive crossreactivity is found among microbial organisms (8). 5) The cross-reactivity issue is further complicated by inter-species reactions. For example, rabbit serum antibody raised against beef heart cytochrome oxidase quantitatively reacted with rat liver cytochrome oxidase (9).
Pari passu, research highlighted the intersection of cross-reactivity and immunopathology. The ability of the antihypertensive drug hydralazine to induce a syndrome similar to spontaneous systemic lupus erythematosus (SLE) in humans was related to the fact that anti-hydralazine serum consisted of antibodies to hydralazine and progressively increasing amounts of antibodies to both single-stranded and native DNA. In essence, antibodies to nuclear antigens were related to SLE, thus indicating that a cross-reactive immune response to drugs might be important in human autoimmunity (10). Likewise, cross-reactivity between the polysaccharide of group A streptococcus and the glycoprotein of heart valves was identified as a primum movens in the pathogenesis of rheumatic heart disease (11).
On the whole, evidence that immune responses are characterized by cross-reactivity accumulated gradually. At that time, such cross-reactivity was adduced to indicate that immune sera contain mixtures of antibody molecules with a large variety of specificities.
ANTIBODIES AND ANTIGENS: CROSS-REACTIVITY AFTER MONOCLONAL ANTIBODIES
The unresolvable complexity of cross-reactivity emerged as a relevant phenomenon with the discovery of monoclonal antibodies (MAbs), i.e., antibodies that were expected to have an exquisitely unique specificity by being produced by identical lymphocytes derived from a unique parent cell (12). This soon seemed not to be the case. 3) Polyspecific reactivity of a MAb (RTE-23) with cytoskeletal proteins (vimentin, keratin, actin), singlestranded DNA, specific synthetic polynucleotides, and cardiolipin (16) was reported. 4) MAbs sharing specificities with mouse natural MAbs were described and characterized in Avrameas' laboratory (17). Furthermore, multiple organreactivity of MAbs to mouse erythrocytes was described (18). 5) Anti-tetanus toxoid MAbs were found to cross-react with diphtheria toxoid, cardiolipin, and DNA, thus indicating that cross-reactive epitopes occur on routinely used toxoid vaccines and self antigens (19). 6) To add complexity, two unrelated MAbs, HyHEL-10 and F9.13.7, recognize the same epitope of hen egg-white lysozyme (20).
Currently, polyspecific reactivity of a single molecular species of antibody continues to be under scientific scrutiny because it represents a major obstacle to the development of immunotherapy effective against devastating infections such as HIV. Indeed, anti-HIV immunotherapy is hampered by the concern of inducing collateral autoimmune phenomena through the induction of humoral/cellular responses that could be cross-reacting with the host proteome. In fact, human monoclonal IgM antibodies to the synthetic peptide MN-24 corresponding to 303-325 residues of gp120 HIV have been found to be reactive not only with different short peptides, but with some macromolecular antigens as well (21). Likewise, the two most broadly reactive HIV-1 envelope gp41 human MAbs, 2F5 and 4E10, are polyspecific autoantibodies reactive with the phospholipid cardiolipin. MAb 2F5 also reacts with histones and the centromere B autoantigen, whereas MAb 4E10 reacts with the systemic SLE autoantigen SS-A/Ro. Both 2F5 and 4E10 also react with HEp-2 human epithelial cells in a diffuse cytoplasmic and nuclear pattern, further revealing polyspecific autoreactivity of both antibodies (22). Taken together, the above mentioned data challenge the concept of antibody exquisite specificity and support the theory of a general polyspecific potential of MAbs (23).
CROSS-REACTIVITY AND THE MOLECULAR MIMICRY HYPOTHESIS
The term "molecular mimicry" was borrowed from the naturalistic sciences debate occurring in the 1930's (24) . In that frame, mimicry accounted for the following sentence: "an insect escapes being eaten because it reminds the enemy of an object which he is not accustomed to eat" (24). Then, in the 1960's, Raymond Damian was the first to translate the naturalistic mimicry concept to the molecular immunological context. In studying parasites, he assumed that parasite antigenic determinants resembling those of the host do not elicit immune reactions because of their being similar to the host (25). Therefore, molecular mimicry initially indicated a camouflage phenomenon to avoid recognition. Historically, this is the first nexus between molecular mimicry and microbial escape from immune surveillance, a phenomenon that remains an object of ongoing scientific discussion (26-30).
However, Damian's molecular mimicry concept took a turn for the contrary. Almost contemporaneously, in 1962 Rowley and Jenkin (31) suggested that infections might lead to autoimmune disease as a result of cross-reactive antibodies or T cells, thus starting a research era aimed at demonstrating that sharing of amino acid sequences or structures between microbes and humans was at the root of autoimmune diseases (32-35). In this new interpretation of the molecular mimicry concept, the immune system "sees", "recognizes" and "attacks" the pathogen sequences/structures. In so acting, the immune system does not pay attention to the fact that the same sequences/structures may be present in the host. Therefore, in reacting against the pathogen, the immune system cross-reacts with identical or similar host sequences/structures, thus breaking the host immunotolerance status and producing autoimmune responses, and, consequently, autoimmune diseases. However, following three decades of intensive research in the field, a causative link between molecular mimicry and human autoimmune diseases is still sub judice, and the molecular mimicry hypothesis has received no validation (36-39).
CROSS-REACTIVITY AND THE PHENOMENON OF MICROBIAL ESCAPE FROM IMMUNE SURVEILLANCE
During the last decade, Kanduc and others (40-46) described a massive peptide overlap between viral proteins and the human proteome. Only a fraction of sequences (less than 10% at the pentapeptide level) are unique to viruses and not found in the human proteome (42). In addition, the exploration of bacterial proteomes for peptides matching the human proteome revealed a sharing of millions of peptide sequences (47-51). In particular, analysis of 40 bacterial proteomes showed that not a single protein is exempt from bacterial motifs at the hexapeptide level (49). The peptide commonality between microbes and humans is illustrated in Figure 1 , showing the ratio of human proteins containing bacterial heptapeptide(s) (99,7%) and those that do not (0.3 %). That is, Figure 1 illustrates the concept that only a tiny fraction of the approximately 30,000 proteins that form the human proteome is exempt from bacterial heptapeptide motifs.
The massive peptide overlap between viruses/bacteria and humans is of impact in the immunologic context and demonstrates the fragility of the molecular mimicry hypothesis. In practice, the data obtained by Kanduc and others (40-51) scientifically validate, at the molecular level, Damian's intuition (23) according to which the parasite antigenic determinants resembling those of the host would not elicit immune reactions because of their being similar to the host. The massive usage of the same peptide blocks in microbial and human proteomes inficiates any causal relationship(s) between sharing of microbial amino acid motifs/structures and autoimmune reactions in humans. The molecular mimicry hypothesis cannot explain autoimmune diseases since, if there were a link between sharing of viral/bacterial peptides and human autoimmune reactions, then the massive extent of viral/bacterial peptide overlap in the human proteome would cause the worldwide human population to suffer from autoimmunity with a 100% incidence. E contrario, it seems that the imponent microbialversus-human peptide overlap offers a proteomic niche for microbes to conceal themselves, thus escaping specific immune recognition. According to Kanduc (52, 53), viruses and bacteria are "a portion" of our human self and are subject to the same tolerogenic mechanisms that characterize human antigens and tissues. This being the case, the self-nonself debate is a pure confrontation between proteomes, with the motifs uniquely owned by microbial entities as unique "nonself" targets of potential immune interactions (54).
Based on the massive peptide overlap between viruses/bacteria and humans, Kanduc (52) also affirms that only those amino acid sequences uniquely expressed in a proteome may have an immune potential. De facto, Kanduc (53-55) finds that almost all epitopes, independent of their being derived from cancer antigens, viral/bacterial proteins, autoantigens or allergens, are located in low-similarity antigen areas. As portrayed in Figure 2 , immunological information is packed into rare peptide motifs (56).
Finally, as a coherent conclusion, Kanduc (52-54) draws a link between the bacterial/viral peptide overlap with the human proteome and immunopathology. In fact, groupings of 5-6 aa are minimal immune determinants in antigen-antibody recognition (57-59, 60 and pertinent references therein). In addition T-cell immune units appear to be contained in an epitopic space defined by 5-6 amino acid residues (61) (62) (63) (64) . In general, it is well known that regulation of immunomodulation can be exerted by pentapeptides (65-72) and, even, tetrapeptides (63, 68) . Hence, vaccination protocols inducing an immune response against whole antigens from viruses/bacteria may also induce a vast array of autoimmune responses in the 
PEPTIDE COMMONALITY, IMMUNE ESCAPE, ADJUVANTED VACCINES AND AUTOIMMUNE CROSS-REACTIONS. A VICIOUS CIRCLE.
As reasoned above and elsewhere (41-46, 48-54), the existence of a widespread peptide commonality between microbes and humans might be a contributing factor in determining microbial immune escape. Consequently, it may also explain the fact that, in general, active vaccines based on antigens from infectious agents produce a weak (or no) immune response. That is, because of immunotolerogenic mechanisms towards repeatedly shared peptide motifs, the human immune system may fail to react against the infectious antigens present in the vaccines. In general, active vaccines are weakly immunogenic. This scarce vaccine immunogenicity has made the use of adjuvants necessary (73) (74) (75) (76) . Adjuvants include inorganic compounds (heavy metals, aluminium hydroxide, aluminium phosphate, and calcium phosphate) (77, 78) , glycosphingolipid and oil emulsions (79) , and products from bacteria (e.g., lipopolysaccharides and lectins) (80) . In practice, adjuvants are highly heterogeneous chemical compounds, with the common property of stimulating immune responses.
On the other hand, adjuvant-induced hyperactivation of the immune system may alter/silence the still ill-defined tolerigenic mechanisms that keep the immune system under control and lead to the avoidance of harmful auto-attacks. Hence, as a logica consecutio, following adjuvanted vaccination, aspecific reactions may occur against host molecules/ structures because of the massive peptide matching between microbes and humans, thus starting autoimmune processes. The type of autoimmune phenomenon and disease that is eventually established will depend on the molecules and organs attacked. For example, attacks against myelin and myelinrelated structures/enzymes may evoke demyelinating diseases, whereas immune reactions against proteins and antigens involved in behavior and/or cognition (neurobeachin, adenosine deaminase, neuroligin, reelin, etc) may cause autism and behavior disorders. In other words, the peptidome platform shared by the antigens present in vaccines and the human host plays a fundamental role in dictating which autoimmune disease occurs following adjuvant-induced immunogenicity.
In synthesis: peptide commonality, microbial immunoevasion, low efficacy of vaccines, adjuvant usage, and autoimmune cross-reactions may constitute a vicious circle leading to autoimmunity following vaccination.
THE FUTURE OF VACCINES: THE CONCEPT OF SEQUENCE UNIQUENESS
In the late 1700's, Edward Jenner introduced vaccination as a tool against infectious diseases. Infecting oneself with the infectious agent to avoid the disease became popular around the world. However, the practice of vaccination was soon under attack (81) . Prominent scientists and philosophers such as Alfred Russell Wallace, Immanuel Kant, and Herbert Spencer, were involved in the critical debate against vaccination (82, 83) . Then as today, the injuriousness of vaccination was under accuse. One statement was that phthisis, cancer, and madness are likely to be the products of vaccination since they increased in frequency after vaccination was introduced (84) . Today, increased autism, childhood leukemia, and cardiac failure are listed among the potential consequences of vaccination.
However, the anti-vaccine debate was and still is sterile (2, 81) . No proof of a direct relationship between vaccination and adverse events has been brought to the attention of the scientific and medical communities, and the presumed vaccination-associated damages have been proposed and analyzed only in epidemiological, and often incomplete, terms.
In this context, the present study represents the first clear-cut meta-analysis of a molecular platform able to rationalize the potential cause-effect link between vaccination and subsequent adverse events. The data discussed here delineate peptide commonality between microbes and humans as the Wallacian "harmonia naturae" protected by immunotolerance and broken by adjuvanted vaccines.
Importantly, the data discussed here also indicate new avenues in vaccinology. Together with a number of recent reports from this lab (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) , the present study demonstrates that only peptide motifs absent or scarcely represented in the host proteome appear to have the potential to evoke a safe, targeted, and effective immune response. Vaccine preparations based on peptide fragments unique to the infectious agent are not only expected to specifically hit the agent without harmful cross-reactions with host proteins, but also may bypass escape mechanisms because of their being practically unknown to the immune system, thus eliminating a main obstacle to an effective immune recognition and destruction of the infectious agent. A successful future looms for vaccines with unique peptide sequences. 
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